(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 September 2025 (11.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/185555 A8

(51) International Patent Classification:
A61K 39/395 (2006.01) *A61P 17/00* (2006.01)
C07K 16/28 (2006.01) *A61P 37/00* (2006.01)

(21) International Application Number:
PCT/CN2025/080184

(22) International Filing Date:
03 March 2025 (03.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2024/079970
04 March 2024 (04.03.2024) CN

(71) Applicant *(for CN only)*: **INMAGENE BIOPHARMACEUTICALS (HANGZHOU) CO., LTD.** [CN/CN]; 2F Building 9, Hexiang Science And Technology Center, Xiasha Road, Qiantang New Area, Hangzhou, Zhejiang 310018 (CN).

(71) Applicant *(for all designated States except CN)*: **INMAGENE PTE. LTD.** [SG/SG]; 20 Emerald Hill Road, 229302 (SG).

(72) Inventors: **SUN, Qiang**; 2F Building 9, Hexiang Science And Technology Center, Xiasha Road, Qiantang New Area, Hangzhou, Zhejiang 310018 (CN). **JIN, Xionghua**; 2F Building 9, Hexiang Science And Technology Center, Xiasha Road, Qiantang New Area, Hangzhou, Zhejiang 310018 (CN). **XU, Zhihao**; 2F Building 9, Hexiang Science And Technology Center, Xiasha Road, Qiantang New Area, Hangzhou, Zhejiang 310018 (CN). **FAN, Pengcheng**; 2F Building 9, Hexiang Science And Technology Center, Xiasha Road, Qiantang New Area, Hangzhou, Zhejiang 310018 (CN).

(74) Agent: **JUN HE LAW OFFICES**; 20/F, China Resources Building 8 Jianguomenbei Avenue, Dongcheng District, Beijing 100005 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:
02 October 2025 (02.10.2025)

(15) Information about Correction:
see Notice of 02 October 2025 (02.10.2025)

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING OX40 TARGETING ANTIBODIES AND USES THEREOF

(57) Abstract: Provided herein are pharmaceutical compositions, formulations and dosage forms containing high concentrations of monoclonal anti-OX40 antibodies. Methods of using these pharmaceutical compositions, formulations and dosage forms, including, for example, treating OX40-associated diseases are also provided herein.

WO 2025/185555 A8